Facet Biotech Corporation

Pdl Biopharma, Inc.

Abbott Biotherapeutics Corp.

Richard Murray

Vinay Bhaskar

Vanitha Ramakrishnan

Debbie Law

Daniel E Afar

David Powers

Ingrid W Caras

Agustin De La Calle

Sun Ho

The invention relates to the identification and generation of antibodies that bind to TMEFF2 proteins which are involved in cancer. Further, the invention provides for the use of these antibodies in the treatment of cancer.

Antibodies against cancer antigen TMEFF2 and uses thereof

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

The present invention provides methods for direct killing of cancer cells using anti-&#x3b1;5&#x3b2;1 antibodies. Generally, the method comprises contacting a cancer cell that expresses &#x3b1;5&#x3b2;1 on its surface with an anti-&#x3b1;5&#x3b2;1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-&#x3b1;5&#x3b2;1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.

Use of anti-&#x3b1;5&#x3b2;1 antibodies to inhibit cancer cell proliferation

Growing community of inventors

Cupertino, CA, United States of America

Richard Murray